TY  - JOUR
AU  - Pacheco-Orozco, Rafael Adrian
AU  - Montealegre-Paez, Lorena
AU  - Cayol, Federico
AU  - Martinez-Gregorio, Hector
AU  - Oliver, Javier
AU  - Frecha, Cecilia
AU  - Vaca-Paniagua, Felipe
AU  - Perdomo, Sandra
PY  - 2020
DO  - 10.1634/theoncologist.2020-0043
UR  - http://hdl.handle.net/10668/16011
T2  - The oncologist
AB  - Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors such as abiraterone and...
LA  - en
PB  - Wiley Periodicals
KW  - Androgen receptor antagonists
KW  - Biomarkers
KW  - Cost savings
KW  - Neoplasm drug resistance
KW  - Prostatic neoplasms
KW  - Therapeutics
KW  - Androstenes
KW  - Benzamides
KW  - Biomarkers
KW  - Colombia
KW  - Drug Resistance, Neoplasm
KW  - Humans
KW  - Latin America
KW  - Male
KW  - Mexico
KW  - Nitriles
KW  - Phenylthiohydantoin
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Protein Isoforms
KW  - Receptors, Androgen
TI  - AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.
TY  - research article
VL  - 25
ER  -